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1. Introduction 
Cystic Fibrosis (CF) is a fatal autosomal recessive disease characterized by abnormal ion 
transport across epithelia, viscous mucus secretions, chronic bacterial infections, and 
inflammation in the airways that result from misprocessed or nonfunctional CFTR (Cystic 
Fibrosis Transmembrane conductance Regulator) chloride channels, normally located at the 
apical membrane of epithelial cells in exocrine tissues. CFTR activity is regulated by the 
Vasoactive Intestinal Peptide (VIP), a neuropeptide with potent anti-inflammatory, 
bronchodilatory and immunomodulatory functions. In airway sub-mucosal glands and 
other exocrine tissues, VIP is the major physiological activator for CFTR-dependent 
secretions, which contribute to local innate defense. When CFTR is defective or absent from 
the apical membrane of epithelial cells, due to mutations in the CFTR gene, airway glands 
no longer secrete in response to VIP stimulation and synergy with acetylcholine is lost. 
Although it is thought that VIP receptors are not altered in CF epithelial tissues, early 
studies have demonstrated that innervations by VIP-containing nerve fibers of the skin 
sweat glands, nasal and intestinal mucosa of CF patients is almost absent compared to 
healthy individuals, suggesting that absence of VIP stimulation could play a central role in 
the development of CF pathology.  
Our group has recently demonstrated that VIP regulates CFTR membrane stability via 
activation of the VPAC1 receptor and the Gi/q signaling cascade in a PKC-dependent 
manner. We also found that prolonged VIP exposure can rescue trafficking to the cell 
membrane and function of F508-CFTR channels; the most commonly found mutation in 
CF.  Our most recent in vivo studies using VIP knock-out (KO) mice provides clear evidence 
of the importance of VIP in maintaining healthy exocrine tissues, and the molecular link, 
between the absence of VIP stimulation and the development of a CF-like phenotype. We 
also observed a corrective effect with exogenous VIP administration, which restored normal 
trafficking and stabilized functional CFTR channels at the apical membrane of epithelial 
cells of the lung and small intestine (Fig. 1&2). 
This mini-review summarizes recent and past findings on the role VIP in CFTR regulation 
and how it relates to the development of CF. 
www.intechopen.com
 
Cystic Fibrosis – Renewed Hopes Through Research 
 
398 
2. VIP historical background: Discovery as a vasodilator peptide in lung and 
intestine and rediscovery as a neuropeptide 
First discovered as a smooth-muscle-relaxant, vasodilator peptide in the lung (Said, 1969), 
VIP was soon thereafter isolated from porcine intestine (Said and Mutt, 1970), chemically 
characterized (Mutt and Said, 1974), and synthesized (Bodanszky et al, 1973). 
A 28 amino-acid residue peptide, VIP is structurally related to several other peptides, said to 
make up a “family,” including pituitary adenylate cyclase-activating peptides (PACAP) 27 
& 38, secretin, glucagon, helodermin, sauvagine, urotensin I, and gastric inhibitory peptide 
(glucose-dependent insulinotropic peptide) (Said, 2006). 
With the aid of specific radioimmunoassay and immunofluorescence techniques, VIP 
immunoreactivity was detected in normal tissues and organs outside of the gastrointestinal 
tract, and found at high concentrations, as well as in certain neurogenic and endocrine 
tumors associated with excessive VIP secretion and high plasma levels (Said and Faloona, 
1975). Eventually, the peptide was "rediscovered" in normal brain and peripheral nerves 
(Said and Rosenberg, 1976), and its true identity was recognized as a neuropeptide with 
neurotransmitter or neuromodulator properties. VIP is now considered to have physiologic 
regulatory influences on multiple organ systems, to be involved in the pathogenesis of 
several human disorders, and to have potential therapeutic benefit in a variety of disorders 
(Said, 1991b). 
3. Role of VIP in exocrine secretion 
As a neuropeptide, VIP was found to richly innervate all exocrine glands, including the 
pancreas, sweat, salivary, lachrymal, bronchial, and intestinal glands. Investigators 
learned that VIP worked in unison with cholinergic nerves, serving primarily to promote 
blood flow, and together with acetylcholine, to regulate and coordinate exocrine function 
(Lundberg et al, 1980). Evidence was accumulating that VIP, acting via receptors on these 
glands (Heinz-Erian et al, 1986), stimulated water and chloride transport across intestinal 
and tracheobronchial mucosa, HCO3- secretion by pancreatic acini, and promoted  
the movement of water and chloride across other epithelial surfaces (Heinz-Erian et al, 
1985). 
4. Is there a link to CF? 
The above observations suggested that VIP exerted a regulatory influence on exocrine 
function, that appeared to run opposite to the observed defects in CF. With my associates 
(Said & colleagues), therefore, we postulated that the exocrine abnormalities of CF might be 
caused by a deficiency of VIP innervation. Accordingly, we examined the presence, 
distribution, and density of VIP-immunoreactive nerves supplying the sweat glands of 
normal subjects and CF patients. We selected sweat glands because: a) they express one of 
the cardinal functional abnormalities of the disease; b) unlike other exocrine organs 
involved in the disease, such as the lungs, sweat glands remain free of infection or 
morphologic changes; and c) they are easily accessible through skin biopsy (Heinz-Erian et 
al, 1985). 
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4.1 Deficient VIP – Containing nerves in CF exocrine tissues 
Normal skin showed a rich network of VIP-immunoreactive nerves around secretory sweat 
gland acini, and a moderate innervation of the reabsorptive ducts. Individual VIP-positive 
nerve fibers were closely associated with basement membrane of both acini and duct cells. 
VIP innervation in CF samples, by contrast, was either absent or minimal both in the acini 
and in the ducts (Heinz-Erian et al, 1985). 
Other than the skin, VIPergic neurons are also present in other sites of important CF 
manifestation such as the mucosa of the small intestinal, the pancreas and the respiratory 
epithelium. As observed in the skin, a deficiency, specifically in VIP-immunoreactive nerves, 
was observed in the nasal and intestinal mucosa of CF patients (Wattchow et al, 1988) while 
other types of nerve fibers were still present. The loss of VIP-immunoreactive nerve fibers was 
not however generalized and normal innervation was observed in intestinal muscles.  
These findings, later confirmed by other investigators (Savage et al, 1990), raised the 
questions: 1) Is the decreased VIP innervation of CF glands and ducts causally related to the 
chloride ion abnormality in CF? and 2) what is the role of VIP, if any, in the pathogenesis, or 
correction, of CF pathology? Both questions remained unanswered for many years to follow. 
4.2 Changes in CF submucosal glands 
In response to VIP stimulation, normal human submucosal glands, in which CFTR is highly 
expressed, secrete low level of mucus which participates in the airways innate defense 
noteworthy by enabling mucociliary clearance (Wine, 2007). In CF glands, however, mucous 
secretion in response to VIP or cAMP elevation is altered (Joo et al, 2002).  Mucus becomes 
more acidic (Song et al, 2006) and more viscous (Jayaraman et al, 2001) compared to normal. 
The same dysfunction is observed in CFTR-KO mice (Ianowski et al, 2007). VIP and 
cholinergic agonists synergistically induce mucous secretion from healthy human and pig 
glands but this synergy is absent in CF tissues (Choi et al, 2007). However, the secretion of 
large amounts of mucus in response to acute stimulation, primarily under the vagal 
pathway1, and cholinergic stimulation are still present although altered (Wine, 2007). 
5. Recent confirmation of a link, from studies of VIP and VIP-KO mice 
We have recently used VIP knockout C57/Bl6 mice to demonstrate in vivo the central role of 
VIP in CFTR regulation and exocrine epithelial tissue integrity.  These mice have been proven 
to be a very good model for airways diseases such as bronchial asthma (Szema et al, 2006; 
Hamidi et al, 2006; Said, 2009). They display airways inflammation and hyper-responsiveness 
to methacholine. They also present moderate pulmonary hypertension, right ventricular 
hypertrophy, and thickened pulmonary arteries (Said et al, 2007). We have used H&E staining 
for pathological assessment of the lung, small intestine and pancreas (Fig. 1). Interestingly, 
changes observed resembled those seen in CF. VIP-KO intestinal tissues had a significant 
increase in goblet and inflammatory cells. In the lung, we observed lymphocyte aggregation, 
increased airway secretion, alveolar thickening and edema. The pancreas presented increased 
secretion and increased infiltration with inflammatory cells surrounding ducts. These 
pathological changes could be reversed, closed to a wild-type phenotype, by VIP treatment 
consisting of intra-peritoneal injections of VIP (15g) every other day for 3 weeks (Fig. 1)  
(Alcolado, 2010). 
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Histology sections of lung (upper panels) and duodenum (lower panels) from wild-type (A & D), VIP-
KO (B & E) and VIP-KO treated (C & F) mice. Samples were embedded in paraffin before sectioning. 5 
μm thick sections were mounted onto microscopy slides before hematoxylin and eosin (H & E) staining. 
Images were taken with a light microscope at 20X magnification. Compared to normal tissue, VIP-KO 
lungs show signs of inflammation (I) and lymphocyte aggregation (dark blue staining), thickening of 
the mucosa around bronchiolar space, thickening of the alveolar walls and the presence of 
inflammatory cells. The bronchiolar epithelium (ep) is also damaged. All these pathological signs are 
reversed to normal after VIP treatment (C). In the duodenum, transversal sections show increased 
amount of goblet cells and epithelium damage in the upper villi of VIP-KO mice tissues. As for the lung, 
these pathological signs are reversed by VIP treatment. 
AS= alveolar sac, B = bronchioles, ep=epithelium, gc = goblet cells, I = inflammation, L = lymphocytes 
aggregation, * alveoli. 
Fig. 1. VIP-KO mice lung and duodenum present pathological signs reversible by VIP 
treatment (adapted from Alcolado, 2010). 
VIP binds to class II seven transmembrane spanning domain G protein-coupled receptors 
(GPCR) on the basolateral membrane of epithelial cells (Laburthe et al, 2007, 2002; Dickson et 
al, 2006; Chastre et al, 1989). VIP can bind to 3 receptors: VPAC1, VPAC2 and PAC1. The 
highest affinity is for VPAC1 (EC50 < 0.1nM) followed by VPAC2 (EC50 =10 nM) and very 
little affinity for PAC1 (EC50 ~40 nM). The PAC1  receptor has a much greater affinity for 
Pituitary Adenylate Cyclase-Activating Polypeptide (EC50 ~0.2 nM) (Dickson and Finlayson, 
2009). Other members of this peptide family, such as secretin and helodermin, can also bind 
to VPAC receptors although with much lower affinity than VIP (Laburthe et al, 2007) . 
Although VIP innervating fibres were found to be absent from CF intestinal mucosa 
(Wattchow et al, 1988), a study on CF foetuses revealed the presence of VIP receptors with 
unaltered pharmacology in the small intestine (Chastre et al, 1989). 
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In the VIP-KO mice model, we confirmed the expression of VPAC1, VPAC2 and PAC1 by 
RT-PCR. Immunoblotting of lung and duodenum tissue lysates revealed unchanged PAC1 
expression in VIP-KO mice tissues compared to wild-type (WT), whereas VPAC 1 and 2 
were found to be more abundant in VIP-KO tissues. These 2 receptors expression level 
remained up-regulated after VIP treatment (Conrad, 2011). CFTR localization was examined 
by immunostaining followed by confocal microscopy (Fig. 2). WT tissues showed CFTR 
predominantly at the apical membrane of epithelial cells in contrast to VIP-KO tissues, 
where CFTR distribution was mainly observed intracellularly. No changes in CFTR protein 
abundance or maturation were observed in immunoblots.  Interestingly, VIP treatment 
restored strong CFTR membrane localization (Fig. 2), confirming the important role of VIP 
chronic exposure to maintain CFTR channels at the membrane, where it can exert its 
function, and for exocrine epithelial tissues integrity. Inflammation and damage observed in 
VIP-KO tissues can be attributed, at least in part, to the lack of CFTR-dependent secretions 
which ultimately depend on VIP stimulation both for acute and long-term regulation of 
CFTR function. These observations provide evidence of the molecular link between early 
observations of deficient VIP-containing fibers innervation of epithelial layers of exocrine 
organs in CF tissues and the absence of CFTR-dependent secretions.  
 
Paraffin embedded tissues (lung: upper panels, duodenum: lower panels) were sliced into 5 μm sections 
and mounted onto microscopy slides before immunostaining with the monoclonal anti-CFTR antibody 
MAB1660 (1:100). Arrows indicate apical CFTR signal. A & D: wild-type, B & E: VIP-KO, C & F: VIP-KO 
treated mice. 
Fig. 2. CFTR localization at the apical membrane of epithelial cells is lost in VIP-KO tissues 
and restored by VIP treatment (adapted from Alcolado, 2010). 
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6. Molecular role of VIP in CFTR regulation 
6.1 Regulation of CFTR activation by VIP acute stimulation 
CFTR is activated mainly by protein kinase A (PKA)-dependent phosphorylation, with 
protein kinase C (PKC) stimulation playing an enhancing and permissive role to subsequent 
responsiveness to PKA (Chappe et al, 2008; Jia et al, 1997), in part through direct 
phosphorylation of conserved consensus sequences in CFTR Regulatory (R) domain 
(Chappe et al, 2003; Chappe et al, 2004). Hormones and neurotransmitters, such as VIP, 
which raise cellular cyclic AMP level, can stimulate acute CFTR channel activity. VIP is the 
most abundant peptide in the airways and the VPAC1 receptor has been shown to stimulate 
CFTR-dependent chloride secretion upon VIP binding through activation of both PKA- and 
PKC-dependent signaling pathways in airway submucosal glands epithelial cell line Calu-3 
(Chappe et al, 2008; Derand et al, 2004).  Although class II GPCR are generally coupled to 
Gs2 and adenylate cyclase activation to increase intracellular cAMP content, numerous 
reports have demonstrated that VIP receptors can couple to alternate G proteins and elicit 
signaling cascades cross-talk involving Gi/q2, PKC and calcium release on top of the 
conventional Gs and cAMP cascade (Derand et al, 2004; Bewley et al, 2006; Chappe et al, 
2008; Sreedharan et al, 1994; Xia et al, 1996; Shreeve et al, 2000; Rafferty et al, 2009) (Fig. 3).  
 
Fig. 3. CFTR regulation by VIP.  
After binding to the VPAC1 receptor, on the basolateral membrane, VIP induces the activation 
of both PKA and PKC signalling cascades. On the right end side of this cartoon is displayed the 
PKC cascade of activation, as observed in our experiments and by others. The Gq protein 
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activates phospholipase C (PLC) which produces inositol tri-phosphate (IP3) and diacylglycerol 
(DAG). IP3 induces calcium release whereas DAG stimulates PKC. PKC can directly 
phosphorylate membrane CFTR on specific sites in the Regulatory domain. The activated PKC 
also binds to the receptor for active kinase C (RAKC1) and translocate to the plasma membrane 
where RAKC1 binds to the PDZ domain 1 of NHERF1 (Na+/H+ Exchanger Regulatory Factor-
1). This complex interacts with CFTR C-terminal, on a PDZ motif, and to ERZIN which anchors 
the whole complex to the actin cytoskeleton. This regulation maintains CFTR at the membrane 
and reduces its endocytosis. The co-localization of PKC and CFTR is thought to maintain CFTR 
phosphorylation which contributes to its activation. We observed that the phosphorylated R 
domain relocates from its initial position, close to the Nucleotide Binding domains (NBD), to a 
new position with increased binding strength. We hypothesize here that re-binding of the 
phosphorylated R domain will further increase CFTR stability at the membrane through 
interaction with the PKC-RAKC1-NHERF1 complex. In parallel (see left side), the VPAC1 
receptor can activate the PKA signalling cascade by associating with the Gs protein which 
activates Adenylyl cyclase (Ac) to produce intracellular cAMP. This second messenger 
stimulates PKA. Direct phosphorylation of the CFTR R domain by PKA activates the channel 
gating. CFTR gating is further enhanced by PKC phosphorylation.  
6.2 Role of VIP in CFTR membrane insertion and stability 
Control of CFTR recycling is an important mechanism for the regulation of CFTR-dependent 
secretions. Adapters and proteins involved in CFTR endocytosis have been studied in detail 
(Ameen et al, 2007; Okiyoneda and Lukacs, 2007), but its regulation by physiological agonists 
is far less well understood and seems to be cell-type specific. Although CFTR function as a 
chloride channel requires apical membrane localization to participate in the regulation of 
exocrine secretions, it is mostly present in recycling endosomes, forming an important 
submembranar pool of mature proteins (Bradbury et al, 1994; Bradbury and Bridges, 1994; 
Webster et al, 1994). CFTR has a relatively long half-life: 16-24 hrs and a rapid turnover, 
although variable among cell lines: 2-16% per minute (Chappe et al, 2008; Lukacs et al, 1993; 
Swiatecka-Urban et al, 2005). CFTR is internalized by clathrin coated vesicles due to the 
presence of a dileucine and tyrosine endocytotic signals in its C-terminal. The tyrosine based 
motif interacts with the clathrin adapter complex AP-2 to enter into clathrin coated pits. CFTR 
also interacts with actin-binding proteins like myosin VI and to N-SWAP to recycle back to the 
plasma membrane via recycling endosomes (Okiyoneda and Lukacs, 2007; Swiatecka-Urban et 
al, 2004; Ganeshan et al, 2006). Conflicting results exist regarding the role of cAMP or other 
second messengers in CFTR recycling probably due to disparity in epithelial cells studied or 
the use of over-expressing systems which might saturate the normal pathway for CFTR 
trafficking. Both PKA and PKC-dependent mechanisms have been reported. 
6.2.1 In intact tissues  
Spiny dogfish shark (Squalus acanthias) rectal glands highly regulate salt secretion upon 
hormonal signals.  These glands express a CFTR ortholog with 72% identity to the human 
CFTR. Acute VIP stimulation of these glands produces an increase in CFTR-mediated 
chloride secretions. Immunofluorescence labeling also revealed a redistribution of CFTR 
from intracellular to apical membrane localization following VIP stimulation (Lehrich et al, 
1998).  
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In rats, a subpopulation of epithelial cells found in the small intestinal villi was identified as 
CFTR High Expresser cells (CHE) (Ameen et al, 1995). In response to VIP stimulation, CFTR 
present in sub-apical vesicular pool redistributed to the apical membrane but returned to 
the intracellular pool after removal of VIP (Ameen et al, 1999; Ameen et al, 2000). 
6.2.2 In cell lines 
Our lab has established that prolonged VIP stimulation of polarized airway epithelial cells 
stabilizes CFTR at the cell surface by reducing its internalization rate by more than 50%. The 
consequence of this regulation is an increase in CFTR-mediated chloride secretion. This was 
demonstrated initially in Calu-3 cells, a widely used model for submucosal gland serous 
cells, which express VPAC1 receptors on their basolateral membrane and wild-type CFTR at 
the apical surface. Analysis of surface proteins by biotinylation and streptavidin extraction 
methods, revealed a large increase in apical CFTR after VIP exposure which was significant 
after 10 min and maximal within 2 hrs of VIP treatment. No changes in total CFTR or the 
proportion of fully glycosylated CFTR were measured in any tested condition, confirming 
that the VIP regulation was on mature CFTR recycling and did not affect its trafficking. 
Interestingly, the signaling cascade involved in this mechanism was VPAC1 and Gi 
mediated and involved the activation of PKC (Chappe et al, 2008). Direct activation of PKC 
by phorbol esters could mimic VIP effect with more than 2 fold increase in apical CFTR after 
2 hrs of treatment. Functional evidence of increased membrane CFTR density after PKC 
stimulation were also reported in the human colon cell line HT29 together with increased 
mucus secretion (Bajnath et al, 1995). Contrary to previous observations in intestinal 
epithelial cells (Ameen et al, 2003; Bradbury and Bridges, 1992), raising intracellular cAMP 
by forskolin had no effect on the amount of CFTR at the apical membrane of Calu-3 cells. It 
is thus evident that VIP effect on CFTR membrane insertion is coupled to different signaling 
pathways in airways and intestinal cells, with the latter having more complex regulation 
possibly depending on the cellular model considered.  
6.2.3 Rescue of F508-CFTR maturation and membrane stability 
The most common mutation in CF is the deletion of a phenylalanine residue at position 508 
(F508) that causes improper folding of the CFTR protein, resulting in its retention in the 
endoplasmic reticulum and proteosomal degradation of the majority of the newly 
synthesized CFTR proteins (Cheng et al, 1990; Kartner et al, 1992; Penque et al, 2000). 
However, part of the F508-CFTR protein can still mature and reach the cell membrane 
where it retains some chloride channel function (Bronsveld et al, 2000; Penque et al, 2000; 
Kopito, 1999).any efforts on CF research are devoted to attempt to rescueF508-CFTR 
defective trafficking to restore normal epithelial function. Interestingly, F508-CFTR retains 
some chloride channel activity when rescued from degradation by low temperature, 
chemical chaperones or other correctors. However, the half-life of the mutant protein is 
considerably shorter than that of the wild-type CFTR, mainly due to instability at the apical 
membrane (Lukacs et al, 1993; Denning et al, 1992; Dormer et al, 2001; Sharma et al, 2001). 
We have investigated the potential rescue and stability at the cell membrane of F508-CFTR 
by VIP treatment in the human nasal epithelial cells JME/CF15, derived from a F508 
homozygous patient (Jefferson et al, 1990). Immunostaining experiments with specific anti-
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CFTR antibodies, followed by confocal microscopy confirmed intracellular localization of 
F508-CFTR under control conditions, at 37°C, whereas membrane localization was 
observed in cells cultured at 27°C for 48hrs (Rafferty et al, 2009). The important finding of 
this study was that when JME/CF15 cells, maintained at physiological temperature (37°C), 
were treated with VIP (300 nM) for 1 or 2 hrs, mature F508-CFTR proteins were observed 
in western blot experiments and immunostaining confirmed localization at the cell 
membrane. Functional assays confirmed the presence of CFTR-dependent chloride secretion 
after VIP treatment at 37°C. In these nasal cells, which express the VPAC1 receptor, we 
found that VIP-dependent rescue of F508-CFTR trafficking was mediated by the PKA-
dependent signaling cascade (Fig. 4). We also found that F508-CFTR membrane insertion 
obtained at low temperature could be enhanced by prolonged VIP treatment (1 to 2 hrs) 
which induced a large increase in F508-CFTR function. As previously observed for wild-
type CFTR, this regulation involved the Gq and PKC signaling cascade but not the Gs - 
PKA cascade (Fig. 4). 
 
Fig. 4. Regulation of F508-CFTR by VIP.  
After binding to the VPAC1 receptor, on the basolateral membrane, VIP induces the 
activation of both PKA and PKC signalling cascades. On the right side of this cartoon is 
displayed the PKC cascade of activation, as observed in our experiments and by others. 
The Gq protein activates phospholipase C (PLC) which produces inositol tri-phosphate 
(IP3) and diacylglycerol (DAG). IP3 induces calcium release whereas DAG stimulates PKC. 
PKC can directly phosphorylate membrane CFTR on specific sites in the Regulatory 
www.intechopen.com
 
Cystic Fibrosis – Renewed Hopes Through Research 
 
406 
domain. The activated PKC also binds to the receptor for active kinase C (RAKC1) and 
translocates to the plasma membrane where RAKC1 binds to the PDZ domain 1 of NHERF1. 
This complex interacts with CFTR C-terminal, on a PDZ motif, and to ERZIN which anchors 
the whole complex to the actin cytoskeleton. This regulation maintains CFTR at the 
membrane and reduces its endocytosis. The co-localization of PKC and CFTR is thought to 
maintain CFTR phosphorylation which contributes to its activation. We observed that the 
phosphorylated R domain relocates from its initial position, close to the Nucleotide Binding 
domains (NBD), to a new unidentified position with increased binding strenght. We 
hypothesize here that re-binding of the phosphorylated R domain will further increase 
CFTR stability at the membrane through interaction with the PKC-RAKC1-NHERF1 
complex. In parallel (see left side), the VPAC1 receptor can activate the PKA signalling 
cascade by associating with the Gs protein which activates Adenylyl cyclase (Ac) to 
produce intracellular cAMP. This second messenger stimulates PKA. Direct 
phosphorylation of the CFTR R domain by PKA activates the channel and is further 
enhanced by PKC phosphorylation. We also observed that the activated PKA contributes to 
F508-CFTR trafficking and insertion to the plasma membrane. We hypothesize that PKA 
effect counteracts the action of the CFTR Associated Ligand (CAL) which had been shown to 
bind to CFTR C-terminal PDZ motif, and compete with NHERF1, to retain CFTR in 
endosomes and target F508-CFTR to lysosomal degradation. 
Evidence from airway cells thus demonstrates that VIP mechanism of regulation of CFTR 
activity involves both PKA and PKC signaling in a synergistic manner to rescue defective 
trafficking of mutant CFTR, activate CFTR gating through direct phosphorylation of its 
regulatory domain, and most importantly, stabilize CFTR channels at the cell surface by 
reducing their internalization rate, thus optimizing CFTR-dependent secretions.  
6.2.4 Role of PKC 
In both recombinant and native systems, we have investigated the role of PKC on VIP-
dependent CFTR membrane stability. PKC isoforms comprise calcium-dependent 
) and calcium-independent novel isoforms (). All necessitate diacyl 
glycerol to be activated (Reyland, 2009; Dempsey et al, 2000; Gallegos and Newton, 2008). 
With specific inhibitors and siRNA treatments we found that only PKC, a novel calcium-
independent isoform, mediated VIP-dependent increase in CFTR membrane stability in 
the JME/CF15 epithelial nasal cells and also in the recombinant BHK cells stably 
expressing wild-type or F508-CFTR (Alcolado et al, 2011).  This is not surprising as PKC 
was previously reported to co-localize with CFTR at the apical membrane of airway 
epithelial cells and to play a permissive role on CFTR-dependent chloride secretion 
(Liedtke and Cole, 1998; Liedtke et al, 2001; Liedtke et al, 2002). The C-terminal of CFTR 
interacts with either CAL or NHERF1. These two scaffolding proteins regulate CFTR 
membrane density in an opposite manner. While CAL, which is mostly found in the trans-
golgi network, promotes CFTR targeting to lysosomal degradation, NHERF1, which is 
localized at the cell apical membrane, rather participate in maintaining CFTR at the 
membrane by tethering it to the actin cytoskeleton (Cheng, J., 2002, 2004). Structural 
studies indicate that CAL and NEHRF1 might compete for the same binding site in CFTR 
C-terminal, and their differential interaction with CFTR is thought to regulate the steady-
state level of mature CFTR present at the apical membrane of epithelial cells (Ladias , 
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2003; Wolde, 2007). Part of this regulation involves activated PKCwhich binds to RACK1 
and translocates to the plasma membrane. RACK1 interacts directly with NHERF1 by 
PDZ domain interaction at the apical membrane of epithelial cells. It is hypothesized that 
the complex composed of PKC – RACK1-NHERF1 interacts with CFTR to regulate its 
membrane stability (Fig. 3 & 4). 
7. Conclusions 
Although VIP binding to the VPAC2 receptor plays an important role in the relaxation of 
smooth muscles and is a matter of intense study for respiratory diseases such as bronchial 
asthma (Hamidi et al, 2006; Alessandrini et al, 1993; Groneberg et al, 2001; Groneberg et al, 
2006; Jaeger et al, 1996; Onoue et al, 2004; Said, 1991a), our recent studies have highlighted 
the important role of the VPAC1 receptor and differential activation of the PKA or PKC 
signalling pathways  in airway epithelial cells to regulate CFTR-dependent secretions. In 
vivo data set VIP, or its analogs, as a potential candidate for the treatment of CF as it corrects 
many features of this disease including the molecular basis. Further investigation of VIP 
potential to rescue exocrine epithelial secretions should be conducted to uncover the large 
potential of this peptide in the treatment of respiratory diseases, which are the third cause of 
hospitalization and death in North America. 
8. Footnotes 
1. Airway defense in response to acute stress such as intense exercise is under the control 
of the vagal nerve pathway (see Kubin, 2006 and Wine, 2007 for review). 
2. G proteins are composed of 3 subunits: ,  and . They mediate signaling cascades 
initiated by ligand binding to membrane receptors of the G protein coupled receptors 
(GPCR) family. Once activated, the  subunit dissociates from  and translocates to a 
target effector: cellular enzymes and ion channels. The  subunits, which mediate most 
of the known signals, comprise 4 different types which will initiate specific signaling 
cascades: s, q, i, 12/13. The s subunit’s effector is the adenylyl cylcase and it initiates 
the cAMP signaling cascade. The q subunit rather activates phospolipase C and 
initiates the calcium and PKC signaling cascades (for review see Musnier, 2010). 
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